

PROGRAM

7th International Winter Conference on Alzheimer's Disease

“ARE WE READY TO TEST NEW THERAPIES IN PRODROMAL AD?”

from
Thursday, 9th of December to Sunday, 12th of December 2010

in
Zürs, Austria

Organized by the:

Austrian Society for Alzheimer's disease



Österreichische Alzheimer Gesellschaft

Organizers and Chairmen:

Ezio Giacobini, Abraham Fisher, Manfred Windisch

Thursday, 9th of December 2010

14:30	WELCOME AND INTRODUCTION Manfred Windisch (Organizer) and Reinhold Schmidt (President of the Austrian Alzheimer Society) Chair: Ezio Giacobini
14:45	OPENING LECTURE Where do we stand with the validation of diagnostic criteria for early AD? <i>Bruno Dubois</i>
15:15	KEYNOTE LECTURE Is amyloid imaging useful for diagnosis of early AD and can it be applied to test new therapies? <i>Agneta Nordberg</i>
15:40	General discussion
16:00	Coffee break
DISCUSSION PANEL 1	CLINICAL BACKGROUND – THE DEFINITION OF THE PROBLEM Chair: Bruno Dubois
16:20	Vascular co-morbidity in mild cognitive impairment <i>Reinhold Schmidt</i>
16:40	Genetic factors modulating cerebrovascular disease <i>Helena Schmidt</i>
17:00	Assessing disease modification in AD by means of fMRI <i>Peter Kapeller</i>
17:20	Conventional and advanced MRI techniques for diagnosis and monitoring of AD <i>Stefan Ropele</i>
17:40	Amyloid PET imaging with florbetapir F18 to identify Alzheimer's disease pathology prior to dementia <i>Chris M. Clark</i>
18:00	Biomarker-based approaches to diagnose prodromal Alzheimer's disease and to detect treatment effects - opportunities and challenges <i>Henrik Zetterberg</i>
18:20	The measure of A β pool in blood may be an effective screening and monitoring tool for clinical trials in Alzheimer's disease <i>Pedro Pesini</i>
18:40	General discussion
19:00	Cocktail reception
19:30	Dinner

Friday, 10th of December 2010

DISCUSSION PANEL 2	COGNITIVE TESTING IN EARLY AD Chair: Bruno Dubois
08:30	Prodromal dementia: How sensitive is neuropsychology? <i>Thomas Benke</i>
08:50	Detecting cognitive deficits and measuring cognitive change in prodromal Alzheimer's disease <i>John Harrison</i>
09:10	New Methodological Strategies for Clinical Trials in Mild Cognitive Impairment <i>Janet Williams</i>
09:30	General discussion
09:50	Coffee break
DISCUSSION PANEL 3	CLINICAL BACKGROUND CONTINUED Chair: Peter Kapeller
10:10	Apathy: Clinical and therapeutic implications <i>Anton Alvarez</i>
10:30	"Reversible Alzheimer Dementia" in a cohort-study <i>Peter Fischer</i>
10:50	Alzheimer bubble – fiction or reality? <i>Klaus-Christian Steinwachs</i>
11:10	Early diagnosis of AD – no treatment!? <i>Hermann-Josef Gertz</i>
11:40	General discussion
12:00	NETWORKING SESSION
14:30	SPECIAL LECTURE: THE INVESTORS POINT OF VIEW Chair: Kees Been
	Despite setbacks, Wall Street continues to embrace Alzheimer's drug candidates - too big to fail <i>Elemer Piros</i>
15:00	General discussion
DISCUSSION PANEL 4	PRECLINICAL TESTING Chair: Eliezer Masliah
15:25	Do we need new animal models for preclinical testing of new therapies for prodromal AD? <i>Manfred Windisch</i>
15:45	General discussion
DISCUSSION PANEL 5	THE IMMUNOTHERAPY OF NEURODEGENERATIVE DISORDERS Chair: Peter Dal-Bianco
16:00	Can Alzheimer's Disease be prevented by a vaccine? <i>Cindy Lemere</i>
16:20	Immunotherapy of Neurodegenerative Diseases <i>Roger Nitsch</i>
16:40	Monoclonal antibodies for treatment of early AD – what do we know? <i>Hansruedi Loetscher</i>
17:00	SupraAntigen vaccine technology - A Novel T Cell Independent Liposomal Amyloid-beta Vaccine for the Treatment of Alzheimer's Disease <i>Andreas Muhs</i>

17:20	General discussion
17:40	Coffee break
DISCUSSION PANEL 6	THE IMMUNOTHERAPY OF NEURODEGENERATIVE DISORDERS Chair: Hansruedi Loetscher
18:00	Development of AFFITOPE vaccines for the treatment of Alzheimer's disease – Results from clinical phase I <i>Achim Schneeberger</i>
18:20	Genetic and neuropathological links of alpha synuclein with Parkinson's disease and related dementias <i>Philipp Kahle</i>
18:40	AFFITOPE based immunotherapeutic strategies for Parkinson's disease <i>Markus Mandler</i>
19:00	Prion-like dissemination of a-synuclein in Parkinson's Disease; prospects for immunotherapy developments <i>Eliezer Masliah</i>
19:20	General discussion
20:00	Dinner

Saturday, 11th of December 2010

MORNING SESSION	SMALL MOLECULES Chair: Roger Nitsch
08:30	Update on small molecules against AD hallmarks: Challenges and perspectives <i>Abraham Fisher</i>
09:00	General discussion
DISCUSSION PANEL 7	GAMMA SECRETETASES-MODULATORS AND INHIBITORS Chair: Israel Hanin
09:20	Measuring Abeta peptides in plasma and CSF: not always what you expect <i>Randy Slemmon</i>
09:40	Update: Gamma-secretase modulators: a treatment for early AD <i>Corinne Augelli-Szafran</i>
10:00	Treatment with the gamma secretase modulator EVP-0015962 improves cognitive deficits and reduces plaque load in tg2576 mice <i>Kathy Rogers</i>
10:20	Pharmacokinetic and pharmacodynamic analysis of the gamma-secretase modulator EVP-0015962 <i>Kevin Felsenstein</i>
10:40	General discussion
11:00	Coffee break
DISCUSSION PANEL 8	ALTERNATIVE WAYS TO TARGET A-BETA Chair: Gerhard Koenig
11:20	Will there ever be a therapy for AD based on ApoE? <i>Danny Michaelson</i>
11:40	Novel anti-amyloid small molecules as potential disease-modifying therapies for Alzheimer's disease <i>Mark Treherne, David Scopes</i>
12:00	Discovery of novel HDAC- inhibitors for CNS indications <i>Holger Patzke</i>
12:20	NPT001, a novel approach for amyloid plaque disaggregation <i>Kimberley Gannon</i>
12:40	General discussion
13:00	NETWORKING SESSION
14:20	SPECIAL LECTURE: THE CEO'S POINT OF VIEW Chair: Klaus-Christian Steinwachs
	Developing drugs for neuro-degenerative diseases, challenges and opportunities for Biotech companies <i>Kees Been</i>
14:40	General discussion
DISCUSSION PANEL 9	GLUTAMINYL CYCLASES – TARGETS TO TREAT ALZHEIMER'S DISEASE AND NEUROINFLAMMATION Chair: Hans-Ulrich Demuth
15:00	Introduction <i>Hans-Ulrich Demuth</i>
15:10	QC-expression enhances pGlu-Abeta formation and mediates phenotypic changes in transgenic mice <i>Stephan Schilling</i>

15:30	Glutaminyl Cyclase Isoenzymes - Involvement in distinct cellular (neuroinflammatory) pathways <i>Holger Cynis</i>
15:50	The development of inhibitors for glutaminyl cyclase as drugs for Alzheimer's disease (AD) <i>Ulrich Heiser</i>
16:10	Biomarker development to accompany preclinics and clinics of QC/isoQC inhibitors in AD and neuroinflammation <i>Martin Kleinschmidt</i>
16:30	General discussion
16:50	Coffee break
DISCUSSION PANEL 10	TAU PROTEIN DIRECTED THERAPIES Chair: Christian Bancher
17:10	Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease <i>Michal Novak</i>
17:30	Targets and biomarkers for disease modification of Alzheimer's disease <i>Christian Czech</i>
17:50	Targeting tau RNA alternative splicing for frontotemporal dementia and related disorders <i>Michael Wolfe</i>
18:10	General discussion
DISCUSSION PANEL 11	NICOTINIC DRUGS Chair: Abraham Fisher
18:30	Mechanism of action of EVP-6124, a nicotinic alpha7 agonist in phase II development for Alzheimer's disease & schizophrenia, surprises & synergies <i>Gerhard Koenig</i>
18:50	Are we ready to test new therapies in prodromal AD? – THE ANSWER <i>Ezio Giacobini</i>
19:10	General discussion
20:00	Dinner

Sunday, 12th of December 2010

Round table discussion from 09:00 am to 11:00 am
Moderation: Ezio Giacobini and Abraham Fisher

“Start of treatment of AD – Is early early enough?”

GOLD SPONSORS:



JSW Lifesciences GmbH
Graz, Austria



AC Immune SA
Lausanne, Switzerland



Affiris AG
Vienna, Austria



EnVivo Pharmaceuticals
Boston, USA



MedAvante, Inc.
New Jersey, USA



Probiodrug AG
Halle, Germany

SILVER SPONSORS:



CoMentis, Inc.
South San Francisco, USA



**NeuroPhage
Pharmaceuticals, Inc.**
Cambridge, USA